资讯  教育  校园  房产  旅游  娱乐  科技  健康  财经  体育  消费  文史  书画  能源

  RSS 设为首页   加入收藏
首页 > 文传商讯 > 正文

Prestige Biopharma Submitted Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar

时间:2022-10-14 11:55:00  来源:文传商讯  作者:
 

SINGAPORE -- (BUSINESS WIRE) --

Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has submitted a request to the U.S. Food and Drug Administration (FDA) for a pre-submission meeting to discuss the company’s planned Biologics License Application (BLA) for its Herceptin Biosimilar, HD201(Tuznue®).

The Biosimilar Biological Product Development (BPD) Type 4 Meeting is to discuss the format and content of a BLA in advance of the final submission. The company will discuss the overall development program of HD201 with the FDA to identify potential filing and review issues. The meeting is expected to take place around November, and the BLA submission by the end of the year.

Prestige Biopharma’s HD201 is a proposed biosimilar to Roche’s Herceptin® (trastuzumab) to be prescribed for the treatment of human epidermal growth factor 2 (HER2) positive breast and metastatic gastric cancer. Trastuzumab targets HER2, which is overexpressed in some types of cancer cells and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

Currently, a New Drug Submission (NDS) for HD201 is under review by Health Canada and a Marketing Authorisation Application (MAA) by the Korea Ministry of Food and Drug Safety. In addition to filing a new MAA to the European Medicines Agency (EMA), the company also plans to apply for authorisation in other advanced biosimilars markets such as UK, Australia, and Singapore.

Lisa Park, CEO of Prestige Biopharma, commented: “This Type 4 Meeting will be the final gate of BLA submission for HD201. In addition to the Bridging Study on biosimilarity of HD201 to US-Herceptin® and the Biosimilar Initial Advisory Meeting with FDA in 2019, we have been through a series of meetings with the FDA on each step of the development to prepare the launch of HD201 in US to help more patients in need. We will take this final step to thoroughly review and finalise the application for FDA’s approval.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20221013006097/en/

CONTACT:

Media Inquiries
Global Communications, Prestige Biopharma
www.prestigebiopharma.com
Yujin Suh
+65-6924-6535
info@prestigebio.com

 
 
 
上一篇:Hero Motocorp为出行新时代“开辟道路”
下一篇:注意-更正并替换:关于在倍乐生艺术场直岛展出草间弥生作品《南瓜》的通知
 
 
 
 
推荐资讯
中国浓香白酒核心产区沉淀一杯出“大国浓香”五粮液
中国浓香白酒核心产区
电影《钢铁意志》今日全国公映 青年歌唱家汤非献唱主题曲
电影《钢铁意志》今日
长安马自达好不好 恩施消费者有话说
长安马自达好不好 恩施
年轻人的座驾 创酷RS恩施受追捧
年轻人的座驾 创酷RS恩
栏目更新
栏目热门
 
 

 
 
网站声明 | 网站简介 | 网站导航 | 频道招商 | 联系方式 | 友情链接
www.hlwang.net 华鲁网